Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in an In Vitro Cystic Fibrosis Sputum Model
Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant <i>Pseudomonas aeruginosa</i> (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and enhanced activ...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI AG
2023-06-01
|
| シリーズ: | Antibiotics |
| 主題: | |
| オンライン･アクセス: | https://www.mdpi.com/2079-6382/12/6/1078 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|